<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">SCIENCE</journal-id>
<journal-title>Science</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Science</abbrev-journal-title>
<issn pub-type="ppub">0036-8075</issn><issn pub-type="epub">1095-9203</issn>
<publisher><publisher-name>American Association for the Advancement of Science</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1234756</article-id>
<article-id pub-id-type="doi">10.1126/science.1234756</article-id>
<article-categories>
<subj-group subj-group-type="article-type"><subject>Report</subject></subj-group>
<subj-group subj-group-type="heading"><subject>Reports</subject></subj-group>
<subj-group subj-group-type="legacy-article-type"><subject>reports</subject></subj-group>
<subj-group subj-group-type="field"><subject>CHEMISTRY</subject></subj-group>
<subj-group subj-group-type="display-ad"><subject>Chemistry</subject><subject>Molecular-Biology</subject><subject>Engineering</subject></subj-group>
</article-categories>
<title-group>
<article-title>Enantioselective Synthesis of Pactamycin, a Complex Antitumor Antibiotic</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Malinowski</surname><given-names>Justin T.</given-names></name><xref ref-type="fn" rid="afn1">*</xref></contrib> <contrib contrib-type="author"><name><surname>Sharpe</surname><given-names>Robert J.</given-names></name><xref ref-type="fn" rid="afn1">*</xref></contrib> <contrib contrib-type="author" corresp="yes"><name><surname>Johnson</surname><given-names>Jeffrey S.</given-names></name><xref ref-type="corresp" rid="cor1">&#x2020;</xref></contrib>
<aff>Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.</aff>
</contrib-group>
<author-notes>
<fn id="afn1" fn-type="equal"><label>*</label>
<p>These authors contributed equally to this work.</p></fn>
<corresp id="cor1"><label>&#x2020;</label>Corresponding author. E-mail: <email xlink:href="jsj@unc.edu">jsj@unc.edu</email></corresp></author-notes>
<pub-date pub-type="ppub"><day>12</day><month>04</month><year>2013</year></pub-date>
<volume>340</volume>
<issue>6129</issue>
<fpage>180</fpage>
<lpage>182</lpage>
<history><date date-type="received"><day>03</day><month>01</month><year>2013</year></date><date date-type="accepted"><day>11</day><month>02</month><year>2013</year></date></history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2013, American Association for the Advancement of Science</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder>American Association for the Advancement of Science</copyright-holder>
</permissions>
<abstract abstract-type="editor"><title>Preparing Pactamycin</title><p>Microbially derived organic compounds often have remarkably intricate structures that confer striking bioactivity, but such complexity may become an impediment to drug development. Pactamycin is one such case&#x2014;a potent antibiotic used to probe ribosome structure and function that in its native form is too cytotoxic for therapeutic application. <bold>Malinowski <italic>et al.</italic></bold> (p. <related-article related-article-type="in-this-issue" vol="340" issue="6129" page="180">180</related-article>; see the Perspective by <bold><related-article related-article-type="in-this-issue" vol="340" page="152" issue="6129">Codelli and Reisman</related-article></bold>) present a 15-step laboratory-scale synthesis of this molecule that offers prospects for the generation of structural analogs that could facilitate further exploratory medicinal research.</p></abstract>
<abstract abstract-type="teaser"><p>A synthetic route to a complex natural product could foster preparation of analogs for exploratory medicinal chemistry. <named-content content-type="related-content">[Also see Perspective by <related-article related-article-type="in-this-issue" vol="340" page="152" issue="6129">Codelli and Reisman</related-article>]</named-content></p></abstract>
<abstract>
<p>Medicinal application of many complex natural products is precluded by the impracticality of their chemical synthesis. Pactamycin, the most structurally intricate aminocyclopentitol antibiotic, displays potent antiproliferative properties across multiple phylogenetic domains, but it is highly cytotoxic. A limited number of analogs produced by genetic engineering technologies show reduced cytotoxicity against mammalian cells, renewing promise for therapeutic applications. For decades, an efficient synthesis of pactamycin amenable to analog derivatizations has eluded researchers. Here, we present a short asymmetric total synthesis of pactamycin. An enantioselective Mannich reaction and symmetry-breaking reduction sequence was designed to enable assembly of the entire carbon core skeleton in under five steps and control critical three-dimensional (stereochemical) functional group relationships. This modular route totals 15 steps and is immediately amenable for structural analog synthesis.</p>
</abstract>
<custom-meta-wrap><custom-meta><meta-name>Editor</meta-name><meta-value>Jake Yeston</meta-value></custom-meta><custom-meta><meta-name>Copyeditor</meta-name><meta-value>Lauren Kmec</meta-value></custom-meta></custom-meta-wrap></article-meta>
</front>
<body>
<p>Complex organic molecules produced by bacteria have been used to treat numerous disease types for nearly a century (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>&#x2013;<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>). However, many naturally derived compounds that exhibit interesting bioactivities are practically inaccessible via synthetic organic chemistry. A natural product&#x2019;s structural complexity can create an insurmountable impediment to the preparation of analogs that might exhibit improved characteristics. An ongoing challenge in the field of synthetic chemistry is the development of methods that close the gap between the efficiency of biosynthetic machinery and laboratory synthesis. Because of the inherent flexibility of the latter, success in this endeavor could provide access to useful structural variants that might otherwise be inaccessible.</p>
<p>Pactamycin (<bold>1</bold>; <xref ref-type="fig" rid="F1">Fig. 1</xref>) was isolated from <italic>Streptomyces pactum</italic> var. <italic>pactum</italic> in 1961 by Argoudelis <italic>et al</italic>. (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>). The bioactivity profile of this natural product is especially notable, as it displays antitumor, antimicrobial, antiviral, and antiprotozoal properties by acting as a universal inhibitor of translocation (<xref ref-type="bibr" rid="R6"><italic>6</italic></xref>&#x2013;<xref ref-type="bibr" rid="R9"><italic>9</italic></xref>). Within the ribosomal subunit in which it interacts, pactamycin mimics an RNA dinucleotide through interactions of its aniline and salicylate moieties with stem loops in the 16<italic>S</italic> RNA (<xref ref-type="bibr" rid="R10"><italic>10</italic></xref>). Unfortunately, pactamycin&#x2019;s therapeutic benefits have yet to be realized, due to high cytotoxicity (median inhibitory concentration of 95 nM against human diploid embryonic cell line MRC-5) (<xref ref-type="bibr" rid="R11"><italic>11</italic></xref>). Pactamycin is a prototypical example of a promising bioactive natural product whose complexity hampers the investigation of structure-activity relationships (SARs) that might lead to a serviceable therapeutic application and/or a better understanding of intrinsic bioactivity.</p>
<fig id="F1" position="float" fig-type="figure"><label>Fig. 1</label><caption>
<title>Structure of pactamycin (1).</title>
<p>Me, methyl.</p>
</caption><graphic xlink:href="340_180_F1"></graphic></fig>
<p>Genetic engineering studies have reignited promise for medicinal application, as 7-deoxy&#x2013; and 8&#x2033;-hydroxy&#x2013;derivatives were isolated and displayed diminished cytotoxicity (<xref ref-type="bibr" rid="R11"><italic>11</italic></xref>&#x2013;<xref ref-type="bibr" rid="R14"><italic>14</italic></xref>). In the context of the work described herein, it is worth noting that Lu <italic>et al</italic>. contend that the structural complexity of <bold>1</bold> renders these and related structural modifications &#x201C;inaccessible by synthetic organic chemistry&#x201D; (<xref ref-type="bibr" rid="R12"><italic>12</italic></xref>). Conversely, we have proceeded from the hypothesis that the genetic engineering approach to pactamycin analogs might be inherently limited by the biosynthetic machinery (<xref ref-type="bibr" rid="R15"><italic>15</italic></xref>, <xref ref-type="bibr" rid="R16"><italic>16</italic></xref>). Though pactamycin is commercially available, a chemical approach to its synthesis could, in principle, provide far greater opportunity and flexibility for discovering and advancing useful compounds. However, this tactic will only be feasible in the presence of an efficient synthesis platform that rapidly develops the appropriate level of structural complexity. In fact, synthetic interest in pactamycin has recently flourished, culminating in the landmark 32-step total synthesis from Hanessian and co-workers (<xref ref-type="bibr" rid="R17"><italic>17</italic></xref>, <xref ref-type="bibr" rid="R18"><italic>18</italic></xref>), as well as numerous partial synthetic studies (<xref ref-type="bibr" rid="R19"><italic>19</italic></xref>&#x2013;<xref ref-type="bibr" rid="R23"><italic>23</italic></xref>). Despite these creative, state-of-the-art approaches, a compelling case can be made that a more practical synthesis solution is needed.</p>
<p>In this Report, we disclose a 15-step total synthesis of pactamycin, which has, in the initial pass, produced the natural product on a milligram scale and a key branch-point intermediate on a gram scale. We emphasized both modular construction and introduction of functionality in the final desired form of pactamycin, enabling an approach amenable to derivatization for analog synthesis. Late-stage introduction of the aniline- and salicylate-binding elements provides an opportunity for future SAR studies.</p>
<p>The recognition of a hidden symmetry in the northeast quadrant of pactamycin (<bold>1</bold>) was critical to our synthetic plan. Depicted in <xref ref-type="fig" rid="F2">Fig. 2A</xref>, the carbon chain connecting C-4 and C-8 can be extracted to a symmetrical &#x03B1;-ureido-2,4-pentanedione <bold>2</bold>. We envisaged simplified formation of the fully substituted C-1 center via a Mannich reaction. Due to the symmetrical methyl ketone substituents at C-1, diastereoselectivity considerations are obviated, allowing for a focus on the enantioselective C-2&#x2013;amino incorporation during the C-1&#x2013;C-2 bond construction. The nascent C-2 stereocenter would then need to direct a site- and diastereoselective diketone monoreduction, setting the C-2/C-1/C-7 stereotriad (red dashed arrows in <xref ref-type="fig" rid="F2">Fig. 2B</xref>). This sequence would provide the entire pactamycin carbon-core skeleton from which modular delivery of various functionality (<xref ref-type="fig" rid="F2">Fig. 2C</xref>) could provide <bold>1</bold> and/or its congeners in rapid fashion.</p>
<fig id="F2" position="float" fig-type="figure"><label>Fig. 2</label><caption>
<title>Synthetic plan enabling modular introduction of functionality.</title>
<p>(<bold>A</bold>) Hidden symmetry recognition within the pactamycin core. Blue dots highlight a five-carbon chain from which to begin the synthesis. Ac, acetyl. (<bold>B</bold>) Red dashed arrows illustrate the pivotal Mannich addition and symmetry-breaking reduction steps. (<bold>C</bold>) Proposed modular construction of pactamycin. The colored components may be varied and introduced for analog synthesis and SAR studies.</p>
</caption><graphic xlink:href="340_180_F2"></graphic></fig>
<p>The first challenge we faced was implementation of the Mannich reaction with an appropriately configured imine electrophile. We were encouraged by results reported by Schaus and co-workers, wherein <italic>Cinchona</italic> alkaloids were effective in catalyzing the enantioselective addition of simple 1,3-dicarbonyls to acyl imines (<xref ref-type="bibr" rid="R24"><italic>24</italic></xref>, <xref ref-type="bibr" rid="R25"><italic>25</italic></xref>). However, the required asymmetric Mannich addition of &#x03B1;-amino&#x2013;substituted dicarbonyls was heretofore unknown. Additionally, with our goal of modular construction in mind, we planned to install the unusual 1,1-dimethylurea in its native form early in our route, a tactic that was expected to obviate the protection, deprotection, and acylation steps that characterize all other pactamycin synthetic studies.</p>
<p>Pronucleophile <bold>2</bold> was synthesized in two steps (<xref ref-type="bibr" rid="R26"><italic>26</italic></xref>) from commodity chemical acetylacetone (2.5 kg ~ $75) and subjected to adapted Mannich conditions with cinnamaldehyde-derived imine <bold>3</bold> (<xref ref-type="fig" rid="F3">Fig. 3</xref>). An evaluation of Lewis bases led to selection of cinchonidine (<bold>7</bold>) as the catalyst of choice, providing Mannich product <bold>4</bold> in 70% isolated yield and 98:2 enantiomeric ratio (er) (94% yield, 84:16 er before removal of the racemate by trituration). An x-ray diffraction study of a derivative (<xref ref-type="bibr" rid="R26"><italic>26</italic></xref>) revealed the formation of the illustrated (<italic>R</italic>) configuration at C-2. Note that this nominally corresponds to the incorrect configuration at C-2, but the advancement of this stereochemical mistake was, in fact, critical to orchestrate downstream stereochemical outcomes and efficiently complete the synthesis (see below). The strategic selection of cinnamyl imine <bold>3</bold> as the Mannich electrophile translated to the installation all five carbons of the pactamycin core, with appropriate functional handles, in this initial C&#x2013;C bond construction. This reaction constitutes a useful advance in the synthesis of differentiated, highly functionalized 1,2-diamines by adaptation of the Schaus conditions to a new nucleophile-electrophile pair; extension to other urea-carbamate combinations can be envisaged.</p>
<fig id="F3" position="float" fig-type="figure"><label>Fig. 3</label><caption>
<title>Mannich reaction and diastereoselective diketone monoreduction.</title>
<p>This two-step sequence installs all pactamycin core carbons, as well as three contiguous stereocenters. Reagents and conditions are as follows: (a) catalyst <bold>7</bold> (20 mol %), dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>), &#x2013;65&#x00B0;C; (b) LTBA, tetrahydrofuran (THF), &#x2013;40&#x00B0;C; (c) <italic>tert</italic>-butyldimethysilyl trifluromethanesulfonate (TBSOTf), 2,6-lutidine, CH<sub>2</sub>Cl<sub>2</sub>, &#x2013;78&#x00B0;C. Ph, phenyl.</p>
</caption><graphic xlink:href="340_180_F3"></graphic></fig>
<p>The proposed desymmetrization of the Mannich adduct (<bold>4</bold> &#x2192; <bold>5</bold>) is complicated by the fact that four diastereomeric monoreduction products are possible. Lithium tri(<italic>tert</italic>-butoxy)aluminum hydride (LTBA) emerged as a superior reducing agent for the desymmetrization, affording hydroxyketone <bold>5</bold> with high diastereoselectivity [&gt;10:1 ratio of <bold>5</bold>:&#x03A3;(other diastereomers)] in 72% yield. This reduction delivered the illustrated (1<italic>R</italic>,2<italic>R</italic>,7<italic>S</italic>)-product; therefore, the incorrect C-2 isomer was parlayed into the correct C-1/C-7 configurations. Subsequent silyl protection of the C-7 hydroxyl gave methyl ketone <bold>6</bold>.</p>
<p>Our attention then shifted to installation of the C-4 side chain and cyclization to complete the cyclopentenone core (<xref ref-type="fig" rid="F4">Fig. 4</xref>). We treated the lithium enolate of ketone <bold>6</bold> with formaldehyde gas (generated in situ by the pyrolysis of paraformaldehyde), which resulted in the single-aldol addition product <bold>8</bold> (<xref ref-type="bibr" rid="R27"><italic>27</italic></xref>, <xref ref-type="bibr" rid="R28"><italic>28</italic></xref>). Alkene ozonolysis furnished aldehyde <bold>9</bold> poised for intramolecular aldol condensation. Cyclization of the &#x03B2;-hydroxy ketone (<xref ref-type="bibr" rid="R29"><italic>29</italic></xref>) was effected upon treatment with sodium methoxide to provide the five-membered pactamycin core structure (<bold>10</bold>) in 50% yield over two steps. Under the basic reaction conditions, the configurationally labile C-2 stereocenter was inverted, and only the correct C-2 isomer was observed in the product enone <bold>10</bold>. This serendipitous event corrected our initial stereochemical error, simplifying subsequent core manipulation.</p>
<fig id="F4" position="float" fig-type="figure"><label>Fig. 4</label><caption>
<title>Elaboration of 6 to pactamycin (1) via modular incorporation of unprotected functionality.</title>
<p>Reagents and conditions are as follows: (a) lithium diisopropylamide, formaldehyde [CH<sub>2</sub>O<sub>(</sub><italic><sub>g</sub></italic><sub>)</sub>], THF, &#x2013;78&#x00B0; to &#x2013;45&#x00B0;C; (b) ozone (O<sub>3</sub>), CH<sub>2</sub>Cl<sub>2</sub>, &#x2013;78&#x00B0;C, then dimethylsulfide (Me<sub>2</sub>S), &#x2013;78&#x00B0;C to room temperature (rt); (c) sodium methoxide (NaOMe), THF, 0&#x00B0;C; (d) hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), sodium hydroxide (NaOH), 7:1 CH<sub>2</sub>Cl<sub>2</sub>:methanol (MeOH), 0&#x00B0;C; (e) chloro(<italic>tert</italic>-butyl)diphenylsilane (TBDPSCl), triethylamine (NEt<sub>3</sub>), dimethylaminopyridine (10 mol %), CH<sub>2</sub>Cl<sub>2</sub>, 0&#x00B0;C to rt; (f) methylmagnesium bromide (MeMgBr), THF, 0&#x00B0;C; (g) 3-acetylaniline (<bold>17</bold>), scandium(III) trifluoromethanesulfonate [Sc(OTf)<sub>3</sub>], toluene, 60&#x00B0;C; (h) TBAF, THF, 0&#x00B0;C; (i) potassium carbonate (K<sub>2</sub>CO<sub>3</sub>), <bold>18</bold>, dimethylacetamide; (j) palladium hydroxide on carbon [Pd(OH)<sub>2</sub>/C], H<sub>2</sub> (1 atm), MeOH.</p>
</caption><graphic xlink:href="340_180_F4"></graphic></fig>
<p>With cyclopentenone <bold>10</bold> in hand, three challenges remained: (i) C-5 methide addition, (ii) C-4 hydroxylation, and (iii) C-3 aniline installation. Inspired by a related approach by Hanessian and co-workers (<xref ref-type="bibr" rid="R17"><italic>17</italic></xref>, <xref ref-type="bibr" rid="R18"><italic>18</italic></xref>), we pursued an epoxidation-nucleophilic aniline ring-opening sequence for access to the <italic>trans</italic>-anilinoalcohol. We anticipated that subsequent nucleophilic methylation of the C-5 ketone would complete the core functionalization. As we explored this proposed route, we discovered the importance of both the order of these steps and the protecting group identity at the C-4 hydroxymethylene.</p>
<p>Nucleophilic epoxidation of enone <bold>10</bold> with basic hydrogen peroxide provided epoxy alcohol <bold>11</bold> with high diastereoselectivity. The sterically demanding <italic>tert</italic>-butyldiphenylsilyl (TBDPS) protecting group was imperative to ensure diastereoselective addition in the subsequent C-5 methylation and to withstand the aniline epoxide-opening conditions. Installation of the silyl group provided ketone <bold>12</bold>, which was then treated with a methyl Grignard reagent to provide carbinol <bold>13</bold>, from the required concave facial trajectory. Nucleophile approach from the convex surface of analogous oxabicyclo[3.1.0]hexane systems is well documented (<xref ref-type="bibr" rid="R17"><italic>17</italic></xref>, <xref ref-type="bibr" rid="R18"><italic>18</italic></xref>, <xref ref-type="bibr" rid="R30"><italic>30</italic></xref>) and would have provided the wrong stereochemical outcome. In the present case, we surmise that this innate preference is overridden, at least in part, via direction by the urea functionality, lending additional support to the strategic decision to incorporate this functionality in its native form from the outset. Epoxide <bold>12</bold> is the crucial branch point for analog synthesis and has been reached in gram quantity on a single pass. The epoxide was subjected to a Sc(OTf)<sub>3</sub>-promoted (OTf, trifluoromethanesulfonate) nucleophilic ring opening with 3-acetylaniline (<bold>17</bold>), proceeding in 66% yield with 18% recovery of the starting material to install the C-3 aniline derivative. The addition of this anilino functionality in its desired, unprotected form completed functionalization of the pactamycin core (<bold>14</bold>).</p>
<p>Deprotection of both silyl ethers was accomplished upon treatment with tetrabutylammonium fluoride (TBAF) to provide tractable tetraol <bold>15</bold> in 90% yield, leaving a highly reactive primary alcohol for selective acylation. A ketene-mediated acylation protocol developed by Serrano <italic>et al</italic>. (<xref ref-type="bibr" rid="R31"><italic>31</italic></xref>) and exploited by Hanessian <italic>et al</italic>. (<xref ref-type="bibr" rid="R17"><italic>17</italic></xref>, <xref ref-type="bibr" rid="R18"><italic>18</italic></xref>) proved effective in completing the sterically encumbered acylation and providing penultimate intermediate <bold>16</bold>. Carboxybenzyl deprotection occurred rapidly under hydrogenolysis conditions with the use of Pearlman&#x2019;s catalyst (<xref ref-type="bibr" rid="R32"><italic>32</italic></xref>) in 82% yield. This deprotection completed the synthesis of pactamycin in 15 steps and 1.9% overall yield. The route is flexible and should be amenable to the preparation of congeners since the introduction of highly functionalized side chains in unprotected form (urea, salicylate, <italic>meta</italic>-acetyl aniline) has been demonstrated.</p>
</body>
<back><app-group><app>
<title>Supplementary Materials</title><supplementary-material>
<p><ext-link ext-link-type="uri" xlink:href="http://www.sciencemag.org/cgi/content/full/340/6129/180/DC1">www.sciencemag.org/cgi/content/full/340/6129/180/DC1</ext-link></p>
<p>Materials and Methods</p>
<p>References (<xref ref-type="bibr" rid="R33"><italic>33</italic></xref>, <xref ref-type="bibr" rid="R34"><italic>34</italic></xref>)</p></supplementary-material></app></app-group>
<ref-list>
<title>References and Notes</title>
<ref id="R1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>Y.-W.</given-names></name><name><surname>Balunas</surname><given-names>M. J.</given-names></name><name><surname>Chai</surname><given-names>H. B.</given-names></name><name><surname>Kinghorn</surname><given-names>A. D.</given-names></name></person-group>, 
<article-title>Drug discovery from natural sources</article-title>. <source>AAPS J.</source> 
<volume>8</volume>, 
<fpage>E239</fpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16796374</pub-id></citation></ref>
<ref id="R2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>von Nussbaum</surname><given-names>F.</given-names></name><name><surname>Brands</surname><given-names>M.</given-names></name><name><surname>Hinzen</surname><given-names>B.</given-names></name><name><surname>Weigand</surname><given-names>S.</given-names></name><name><surname>Habich</surname><given-names>D.</given-names></name></person-group>, 
<article-title>Antibacterial natural products in medicinal chemistry&#x2014;Exodus or revival?</article-title> <source>Angew. Chem. Int. Ed.</source> 
<volume>45</volume>, 
<fpage>5072</fpage> (<year>2006</year>). <pub-id pub-id-type="doi">10.1002/anie.200600350</pub-id></citation></ref>
<ref id="R3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drahl</surname><given-names>C.</given-names></name><name><surname>Cravatt</surname><given-names>B. F.</given-names></name><name><surname>Sorensen</surname><given-names>E. J.</given-names></name></person-group>, 
<article-title>Protein-reactive natural products</article-title>. <source>Angew. Chem. Int. Ed.</source> 
<volume>44</volume>, 
<fpage>5788</fpage> (<year>2005</year>). <pub-id pub-id-type="doi">10.1002/anie.200500900</pub-id></citation></ref>
<ref id="R4"><label>4</label><citation citation-type="book">K. Nakanishi, in <italic>Comprehensive Natural Products Chemistry</italic>, D. Barton <italic>et al</italic>., Eds. (Elsevier, New York, 1999), vol. 1, p. 23.</citation></ref>
<ref id="R5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Argoudelis</surname><given-names>A. D.</given-names></name><name><surname>Jahnke</surname><given-names>H. K.</given-names></name><name><surname>Fox</surname><given-names>J. A.</given-names></name></person-group>, 
<article-title>Pactamycin, a new antitumor antibiotic. II. Isolation and characterization</article-title>. <source>Antimicrob. Agents Chemother.</source> 
<volume>1962</volume>, 
<fpage>191</fpage> (<year>1962</year>).</citation></ref>
<ref id="R6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dinos</surname><given-names>G.</given-names></name><etal /></person-group>., 
<article-title>Dissecting the ribosomal inhibition mechanisms of edeine and pactamycin: The universally conserved residues G693 and C795 regulate P-site RNA binding</article-title>. <source>Mol. Cell</source> 
<volume>13</volume>, 
<fpage>113</fpage> (<year>2004</year>). <pub-id pub-id-type="doi">10.1016/S1097-2765(04)00002-4</pub-id><pub-id pub-id-type="pmid">14731399</pub-id></citation></ref>
<ref id="R7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weller</surname><given-names>D. D.</given-names></name><name><surname>Haber</surname><given-names>A.</given-names></name><name><surname>Rinehart</surname><given-names>K. L.</given-names><suffix>Jr.</suffix></name><name><surname>Wiley</surname><given-names>P. F.</given-names></name></person-group>, 
<article-title>Carbon-13 nuclear magnetic resonance assignments of pactamycin and related compounds</article-title>. <source>J. Antibiot.</source> 
<volume>31</volume>, 
<fpage>997</fpage> (<year>1978</year>). <pub-id pub-id-type="doi">10.7164/antibiotics.31.997</pub-id><pub-id pub-id-type="pmid">711622</pub-id></citation></ref>
<ref id="R8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiley</surname><given-names>P. F.</given-names></name><name><surname>Jahnke</surname><given-names>H. K.</given-names></name><name><surname>MacKellar</surname><given-names>F.</given-names></name><name><surname>Kelly</surname><given-names>R. B.</given-names></name><name><surname>Argoudelis</surname><given-names>A. D.</given-names></name></person-group>, 
<article-title>The structure of pactamycin</article-title>. <source>J. Org. Chem.</source> 
<volume>35</volume>, 
<fpage>1420</fpage> (<year>1970</year>). <pub-id pub-id-type="doi">10.1021/jo00830a035</pub-id><pub-id pub-id-type="pmid">5440331</pub-id></citation></ref>
<ref id="R9"><label>9</label><citation citation-type="confproc">D. J. Duchamp, abstract no. 23 presented at the American Crystallographic Association Winter Meeting, Albuquerque, NM, 3 to 7 April 1972.</citation></ref>
<ref id="R10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brodersen</surname><given-names>D. E.</given-names></name><etal /></person-group>., 
<article-title>The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit</article-title>. <source>Cell</source> 
<volume>103</volume>, 
<fpage>1143</fpage> (<year>2000</year>). <pub-id pub-id-type="doi">10.1016/S0092-8674(00)00216-6</pub-id><pub-id pub-id-type="pmid">11163189</pub-id></citation></ref>
<ref id="R11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iwatsuki</surname><given-names>M.</given-names></name><etal /></person-group>., 
<article-title>Jogyamycin, a new antiprotozoal aminocyclopentitol antibiotic, produced by Streptomyces sp. a-WM-JG-16.2</article-title>. <source>J. Antibiot.</source> 
<volume>65</volume>, 
<fpage>169</fpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1038/ja.2011.136</pub-id><pub-id pub-id-type="pmid">22234298</pub-id></citation></ref>
<ref id="R12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>Roongsawang</surname><given-names>N.</given-names></name><name><surname>Mahmud</surname><given-names>T.</given-names></name></person-group>, 
<article-title>Biosynthetic studies and genetic engineering of pactamycin analogs with improved selectivity toward malarial parasites</article-title>. <source>Chem. Biol.</source> 
<volume>18</volume>, 
<fpage>425</fpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1016/j.chembiol.2011.01.016</pub-id><pub-id pub-id-type="pmid">21513878</pub-id></citation></ref>
<ref id="R13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Otoguro</surname><given-names>K.</given-names></name><etal /></person-group>., 
<article-title>Promising lead compounds for novel antiprotozoals</article-title>. <source>J. Antibiot.</source> 
<volume>63</volume>, 
<fpage>381</fpage> (<year>2010</year>). <pub-id pub-id-type="doi">10.1038/ja.2010.50</pub-id><pub-id pub-id-type="pmid">20661239</pub-id></citation></ref>
<ref id="R14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dobashi</surname><given-names>K.</given-names></name><etal /></person-group>., 
<article-title>8&#x2033;-Hydroxypactamycin and 7-deoxypactamycin, new members of the pactamycin group</article-title>. <source>J. Antibiot.</source> 
<volume>39</volume>, 
<fpage>1779</fpage> (<year>1986</year>). <pub-id pub-id-type="doi">10.7164/antibiotics.39.1779</pub-id><pub-id pub-id-type="pmid">3818452</pub-id></citation></ref>
<ref id="R15"><note><label>15</label>
<p>For an instructive debate on this point, please see (<xref ref-type="bibr" rid="R16"><italic>16</italic></xref>).</p></note></ref>
<ref id="R16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keasling</surname><given-names>J. D.</given-names></name><name><surname>Mendoza</surname><given-names>A.</given-names></name><name><surname>Baran</surname><given-names>P. S.</given-names></name></person-group>, 
<article-title>Synthesis: A constructive debate</article-title>. <source>Nature</source> 
<volume>492</volume>, 
<fpage>188</fpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1038/492188a</pub-id><pub-id pub-id-type="pmid">23235869</pub-id></citation></ref>
<ref id="R17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanessian</surname><given-names>S.</given-names></name><etal /></person-group>., 
<article-title>Total synthesis of pactamycin</article-title>. <source>Angew. Chem. Int. Ed.</source> 
<volume>50</volume>, 
<fpage>3497</fpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1002/anie.201008079</pub-id></citation></ref>
<ref id="R18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanessian</surname><given-names>S.</given-names></name><name><surname>Vakiti</surname><given-names>R. R.</given-names></name><name><surname>Dorich</surname><given-names>S.</given-names></name><name><surname>Banerjee</surname><given-names>S.</given-names></name><name><surname>Desch&#x00EA;nes-Simard</surname><given-names>B.</given-names></name></person-group>, 
<article-title>Total synthesis of pactamycin and pactamycate: a detailed account</article-title>. <source>J. Org. Chem.</source> 
<volume>77</volume>, 
<fpage>9458</fpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1021/jo301638z</pub-id><pub-id pub-id-type="pmid">23083207</pub-id></citation></ref>
<ref id="R19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsujimoto</surname><given-names>T.</given-names></name><name><surname>Nishikawa</surname><given-names>T.</given-names></name><name><surname>Urabe</surname><given-names>D.</given-names></name><name><surname>Isobe</surname><given-names>M.</given-names></name></person-group>, 
<article-title>Synthesis of functionalized cyclopentane for pactamycin, a potent antitumor antibiotic</article-title>. <source>Synlett</source> 
<volume>2005</volume>, 
<fpage>433</fpage> (<year>2005</year>).</citation></ref>
<ref id="R20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knapp</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name></person-group>, 
<article-title>Synthesis of the oxygenated pactamycin core</article-title>. <source>Org. Lett.</source> 
<volume>9</volume>, 
<fpage>1359</fpage> (<year>2007</year>). <pub-id pub-id-type="doi">10.1021/ol0702472</pub-id><pub-id pub-id-type="pmid">17338541</pub-id></citation></ref>
<ref id="R21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malinowski</surname><given-names>J. T.</given-names></name><name><surname>McCarver</surname><given-names>S. J.</given-names></name><name><surname>Johnson</surname><given-names>J. S.</given-names></name></person-group>, 
<article-title>Diastereocontrolled construction of pactamycin&#x2019;s complex ureido triol functional array</article-title>. <source>Org. Lett.</source> 
<volume>14</volume>, 
<fpage>2878</fpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1021/ol301140c</pub-id><pub-id pub-id-type="pmid">22617016</pub-id></citation></ref>
<ref id="R22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haussener</surname><given-names>T. J.</given-names></name><name><surname>Looper</surname><given-names>R. E.</given-names></name></person-group>, 
<article-title>Access to the pactamycin core via an epoxide opening cascade</article-title>. <source>Org. Lett.</source> 
<volume>14</volume>, 
<fpage>3632</fpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1021/ol301461e</pub-id></citation></ref>
<ref id="R23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>N.</given-names></name><name><surname>Tsujimoto</surname><given-names>T.</given-names></name><name><surname>Nakazaki</surname><given-names>A.</given-names></name><name><surname>Isobe</surname><given-names>M.</given-names></name><name><surname>Nishikawa</surname><given-names>T.</given-names></name></person-group>, 
<article-title>Synthetic studies on pactamycin, a potent antitumor antibiotic</article-title>. <source>RSC Adv.</source> 
<volume>2</volume>, 
<fpage>9448</fpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1039/c2ra21060f</pub-id></citation></ref>
<ref id="R24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>S.</given-names></name><name><surname>Taoka</surname><given-names>B. M.</given-names></name><name><surname>Ting</surname><given-names>A.</given-names></name><name><surname>Schaus</surname><given-names>S. E.</given-names></name></person-group>, 
<article-title>Asymmetric Mannich reactions of &#x03B2;-keto esters with acyl imines catalyzed by cinchona alkaloids</article-title>. <source>J. Am. Chem. Soc.</source> 
<volume>127</volume>, 
<fpage>11256</fpage> (<year>2005</year>). <pub-id pub-id-type="doi">10.1021/ja0537373</pub-id><pub-id pub-id-type="pmid">16089450</pub-id></citation></ref>
<ref id="R25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ting</surname><given-names>A.</given-names></name><name><surname>Lou</surname><given-names>S.</given-names></name><name><surname>Schaus</surname><given-names>S. E.</given-names></name></person-group>, 
<article-title>Highly diastereoselective asymmetric Mannich reactions of 1,3-dicarbonyls with acyl imines</article-title>. <source>Org. Lett.</source> 
<volume>8</volume>, 
<fpage>2003</fpage> (<year>2006</year>). <pub-id pub-id-type="doi">10.1021/ol060304b</pub-id><pub-id pub-id-type="pmid">16671767</pub-id></citation></ref>
<ref id="R26"><note><label>26</label>
<p>For details, please refer to the supplementary materials on <italic>Science</italic> Online.</p></note></ref>
<ref id="R27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Feng</surname><given-names>J.-P.</given-names></name><name><surname>Wang</surname><given-names>W.-H.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>X.-P.</given-names></name></person-group>, 
<article-title>Total synthesis and correct absolute configuration of malyngamide U</article-title>. <source>J. Org. Chem.</source> 
<volume>72</volume>, 
<fpage>2344</fpage> (<year>2007</year>). <pub-id pub-id-type="doi">10.1021/jo061456n</pub-id><pub-id pub-id-type="pmid">17346080</pub-id></citation></ref>
<ref id="R28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trost</surname><given-names>B. M.</given-names></name><name><surname>Haffner</surname><given-names>C. D.</given-names></name><name><surname>Jebaratnam</surname><given-names>D. J.</given-names></name><name><surname>Krische</surname><given-names>M. J.</given-names></name><name><surname>Thomas</surname><given-names>A. P.</given-names></name></person-group>, 
<article-title>The palladium-catalyzed enyne cycloisomerization reaction in a general approach to the asymmetric syntheses of the picrotoxane sesquiterpenes. Part I. First-generation total synthesis of corianin and formal syntheses of picrotoxinin and picrotin</article-title>. <source>J. Am. Chem. Soc.</source> 
<volume>121</volume>, 
<fpage>6183</fpage> (<year>1999</year>). <pub-id pub-id-type="doi">10.1021/ja9901821</pub-id></citation></ref>
<ref id="R29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verlaak</surname><given-names>J. M. J.</given-names></name><name><surname>Klunder</surname><given-names>A. J. H.</given-names></name><name><surname>Zwanenburg</surname><given-names>B.</given-names></name></person-group>, 
<article-title>Stereospecific total synthesis of (&#x00B1;) pentenomycins by flash vacuum thermolysis of substituted tricyclo[5.2.1.0]decenones</article-title>. <source>Tetrahedron Lett.</source> 
<volume>23</volume>, 
<fpage>5463</fpage> (<year>1982</year>).</citation></ref>
<ref id="R30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Meyer</surname><given-names>K.</given-names></name><name><surname>Greaney</surname><given-names>M. F.</given-names></name></person-group>, 
<article-title>Synthesis of (&#x00B1;)-merrilactone A and (&#x00B1;)-anislactone A</article-title>. <source>Angew. Chem. Int. Ed.</source> 
<volume>49</volume>, 
<fpage>9250</fpage> (<year>2010</year>). <pub-id pub-id-type="doi">10.1002/anie.201005156</pub-id></citation></ref>
<ref id="R31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Serrano</surname><given-names>P.</given-names></name><name><surname>Llebaria</surname><given-names>A.</given-names></name><name><surname>Delgado</surname><given-names>A.</given-names></name></person-group>, 
<article-title>An unexpected chelation-controlled Yb(OTf)<sub>3</sub>-catalyzed aminolysis and azidolysis of cyclitol epoxides</article-title>. <source>J. Org. Chem.</source> 
<volume>67</volume>, 
<fpage>7165</fpage> (<year>2002</year>). <pub-id pub-id-type="doi">10.1021/jo0261146</pub-id><pub-id pub-id-type="pmid">12354019</pub-id></citation></ref>
<ref id="R32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pearlman</surname><given-names>W. M.</given-names></name></person-group>, 
<article-title>Noble metal hydroxides on carbon nonpyrophoric dry catalysts</article-title>. <source>Tetrahedron Lett.</source> 
<volume>8</volume>, 
<fpage>1663</fpage> (<year>1967</year>). <pub-id pub-id-type="doi">10.1016/S0040-4039(00)70335-2</pub-id></citation></ref>
<ref id="R33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trost</surname><given-names>B. M.</given-names></name><name><surname>Lupton</surname><given-names>D. W.</given-names></name></person-group>, 
<article-title>Dinuclear zinc-catalyzed enantioselective Aza-Henry reaction</article-title>. <source>Org. Lett.</source> 
<volume>9</volume>, 
<fpage>2023</fpage> (<year>2007</year>). <pub-id pub-id-type="doi">10.1021/ol070618e</pub-id><pub-id pub-id-type="pmid">17439228</pub-id></citation></ref>
<ref id="R34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.-B.</given-names></name><name><surname>Hong</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>Y.-G.</given-names></name></person-group>, 
<article-title>A cascade approach to pyridines from 2-azido-2,4-dienoates amd &#x03B1;-diazocabonyl compounds</article-title>. <source>J. Org. Chem.</source> 
<volume>74</volume>, 
<fpage>903</fpage> (<year>2009</year>). <pub-id pub-id-type="doi">10.1021/jo802159g</pub-id><pub-id pub-id-type="pmid">19067543</pub-id></citation></ref>
</ref-list>
<ack>
<title>Acknowledgments</title><p>The project described was supported by award no. R01 GM084927 from the National Institute of General Medical Sciences. J.T.M. acknowledges an American Chemical Society Division of Organic Chemistry graduate fellowship. R.J.S acknowledges an NSF graduate research fellowship. X-ray crystallography was performed by P. White (University of North Carolina). The Cambridge Crystallographic Data Centre (CCDC) contains the supplementary crystallographic data for this paper, under deposition no. 914582. These data can be obtained free of charge from via <ext-link ext-link-type="uri" xlink:href="http://www.ccdc.cam.ac.uk/data_request/cif">www.ccdc.cam.ac.uk/data_request/cif</ext-link>. A patent application on the route and compounds presented in this paper has been filed through the University of North Carolina.</p>
</ack></back>
</article>